目的:探讨妊娠期糖尿病(GDM)孕妇血、脐血及胎盘组织内脂素(visfatin)在胎儿宫内发育的作用。方法:选取行择期剖宫产终止妊娠的孕妇77例,其中GDM组30例,肥胖组20例,正常对照组27例。ELLISA法测定血清visfatin水平,荧光定量PCR及免疫蛋白印迹(western)测定胎盘组织visfatin的表达。结果:GDM组母血和脐血Visfatin水平分别为(6.72±3.79)ng/ml和(14.33±4.99)ng/ml,明显低于正常对照组(8.87±4.08)ng/ml和(24.16±9.09)ng/ml,差异有统计学意义(P<0.01);GDM组脐血Visfatin与胎盘组织visfatin mRNA表达呈正相关(P<0.05),正常组及GDM组脐血visfatin水平与新生儿PI呈负相关(P<0.01)。结论:在妊娠末期,GDM患者血清Visfatin降低参与了GDM的发生;在GDM时胎盘visfatin在胎儿宫内生长发育方面起一定作用。 Objective: To investigate the role of visfatin in fetal blood and umbilical blood in gestational diabetes mellitus (GDM) and placenta. Methods: Totally 77 pregnant women undergoing elective cesarean termination of pregnancy were enrolled. Among them, 30 were GDM group, 20 were obese group and 27 were normal control group. Serum visfatin level was measured by ELLISA, and the expression of visfatin in placenta was detected by fluorescence quantitative PCR and western blot. Results: The levels of Visfatin in maternal blood and umbilical cord blood in GDM group were (6.72 ± 3.79) ng / ml and (14.33 ± 4.99) ng / ml respectively, which were significantly lower than those in normal control group (8.87 ± 4.08) ng / ml and ) ng / ml, the difference was statistically significant (P <0.01). There was a positive correlation between visfatin mRNA and cord blood visfatin mRNA level in cord blood of GDM group (P <0.05) Related (P <0.01). Conclusions: Visfatin decreased in GDM patients during the third trimester of pregnancy, which is involved in the development of GDM. Placental visfatin plays an important role in fetal intrauterine growth in GDM.